These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17495970)

  • 1. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
    Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
    Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells.
    Wehner R; Löbel B; Bornhäuser M; Schäkel K; Cartellieri M; Bachmann M; Rieber EP; Schmitz M
    Int J Cancer; 2009 Jan; 124(2):358-66. PubMed ID: 18942710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells.
    Wehner R; Bitterlich A; Meyer N; Kloß A; Schäkel K; Bachmann M; Schmitz M
    Int J Cancer; 2013 Mar; 132(6):1351-9. PubMed ID: 22907335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
    Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
    Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
    Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
    Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).
    Arpinati M; Chirumbolo G; Nicolini B; Agostinelli C; Rondelli D
    Bone Marrow Transplant; 2009 Feb; 43(3):253-9. PubMed ID: 18806836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.
    Nencioni A; Schwarzenberg K; Brauer KM; Schmidt SM; Ballestrero A; Grünebach F; Brossart P
    Blood; 2006 Jul; 108(2):551-8. PubMed ID: 16537813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal photopheresis efficiently impairs the proinflammatory capacity of human 6-sulfo LacNAc dendritic cells.
    Gerner M; Hölig K; Wehner R; Zhao S; Schäkel K; Bachmann MP; Rieber EP; Bornhäuser M; Schmitz M
    Transplantation; 2009 Apr; 87(8):1134-9. PubMed ID: 19384158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bidirectional crosstalk between human dendritic cells and natural killer cells.
    Wehner R; Dietze K; Bachmann M; Schmitz M
    J Innate Immun; 2011; 3(3):258-63. PubMed ID: 21411969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
    Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
    Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
    Schumacher LY; Vo DD; Garban HJ; Comin-Anduix B; Owens SK; Dissette VB; Glaspy JA; McBride WH; Bonavida B; Economou JS; Ribas A
    J Immunol; 2006 Apr; 176(8):4757-65. PubMed ID: 16585569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
    Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
    Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
    Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
    Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.